文章：

针对转移性神经内分泌肿瘤，在布兰德栓塞术后应用肽受体放射性核素治疗（PRRT）的安全性与疗效评估

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors

原文发布日期：30 July 2024

DOI: 10.3390/cancers16152703

类型: Article

开放获取: 是

英文摘要：

Rationale: Evaluating the long-term safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors (mNETs) who have undergone prior bland hepatic transarterial embolization (TAE).Methods: Retrospective review of mNET patients who received PRRT with177Lu-DOTATATE between 4/2018 and 02/2022 with and without prior TAE. The most recent clinical, imaging, and laboratory findings, including hepatic Common Terminology Criteria for Adverse Events v5.0, were compared to pre-PRRT.Results: 171 patients (95 M, 76 F, median age = 66) with mNET of different primary sites (9 foregut, 100 midgut, 9 hindgut, 44 pancreas, 9 unknown) received at least 1 cycle of PRRT with at least 6 months of follow-up, 110 of whom were embolization-naïve and 61 who had prior TAE. The median follow up was 22 months (range: 6–43). Patients with prior TAE had higher liver tumor burden on average than patients without prior TAE; however, the difference was not statistically significant (p= 0.06). There was no significant difference in the rates of G3 or G4 hepatotoxicity (p= 0.548 andp= 0.999, respectively) in patients who underwent prior TAE and those who were TAE-naïve. The hepatic progression-free survival was 22.9 months in TAE-naïve patients and 25.7, 20.2, and 12.8 months in patients with 1, 2, and 3 prior TAE treatments, respectively.Conclusion: Peptide receptor radionuclide therapy following transarterial bland embolization for mNET is safe and effective.

摘要翻译： 

研究背景：旨在评估肽受体放射性核素治疗（PRRT）对既往接受过单纯肝动脉栓塞术（TAE）的转移性神经内分泌肿瘤（mNET）患者的长期安全性和有效性。 研究方法：回顾性分析2018年4月至2022年2月期间接受¹⁷⁷Lu-DOTATATE PRRT治疗的mNET患者，比较既往接受TAE与未接受TAE患者的临床资料。将治疗前与最近随访的临床、影像学及实验室检查结果（包括采用不良事件通用术语标准v5.0评估的肝脏毒性）进行对比分析。 研究结果：171例不同原发部位mNET患者（男性95例，女性76例，中位年龄66岁；前肠来源9例，中肠100例，后肠9例，胰腺44例，原发不明9例）接受至少1个周期PRRT治疗并完成至少6个月随访，其中未接受栓塞治疗者110例，既往接受TAE者61例。中位随访时间22个月（范围：6-43个月）。既往接受TAE患者的平均肝脏肿瘤负荷高于未栓塞患者，但差异无统计学意义（p=0.06）。两组患者在3级或4级肝毒性发生率方面均无显著差异（分别为p=0.548和p=0.999）。未栓塞患者的肝脏无进展生存期为22.9个月，而既往接受1次、2次和3次TAE治疗的患者分别为25.7个月、20.2个月和12.8个月。 研究结论：对于转移性神经内分泌肿瘤患者，在经动脉单纯栓塞术后实施肽受体放射性核素治疗安全有效。

原文链接：

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors